Gyre Therapeutics, Inc. (GYRE:NASDAQ) closed at $5.90 on October 21, 2026, down 4.38% on the day. The stock trades 35.4% below its 52-week high of $9.14 and 8.5% above its 52-week low of $5.44. Over the past year, it lost 21.8%. Gyre Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 21, 2025, GYRE closed higher on 111 days (44%). Its best day was January 5, 2026 (+16.30%) and its worst was May 7, 2026 (-12.06%). The stock moved 10% or more in a single session 4 times.
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
Find more stocks like GYRE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.